CN¥ 14.88
Key Takeaways
Risk factor
Good trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very poor margins and returns
Data is available to registered users only
Data is available to registered users only
About
Changchun BCHT Biotechnology Co. Ltd. is a biopharmaceutical enterprise primarily focused on the research, development, production, and global commercialization of vaccines designed for human use. Its extensive product portfolio features key immunizations such as attenuated (live) herpes zoster and varicella vaccines, alongside a live, nasal, and freeze-dried influenza vaccine, and a rabies vaccine utilizing vero cell technology. This company was established in 2004 and is headquartered in Changchun, China.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Data is available to registered users only